Signifor (Pasireotide) for Hypoglycemia
Signifor is NOT FDA-approved for treating hypoglycemia and is actually contraindicated for this purpose—it is only approved for Cushing's disease where it causes hyperglycemia as a side effect. However, emerging evidence shows pasireotide can be effective off-label for refractory hyperinsulinemic hypoglycemia when conventional therapies fail, particularly in insulinoma patients 1.
Critical Context: Understanding the Paradox
Pasireotide's FDA indication is for Cushing's disease, where hyperglycemia is a major adverse effect requiring intensive glucose monitoring 1. The drug works by inhibiting insulin secretion through somatostatin receptor 5 (SSTR5), which is precisely why it can treat insulin-excess hypoglycemia off-label—but this represents a complete reversal of its approved use.
When to Consider Pasireotide for Hypoglycemia
Use pasireotide only after documented failure of all conventional therapies in patients with endogenous hyperinsulinemic hypoglycemia 2, 3, 4. The 2009 Endocrine Society guidelines recommend a systematic workup for hypoglycemia but do not address pasireotide, as it wasn't available for this indication 5.
Appropriate Clinical Scenarios:
- Insulinoma patients who cannot undergo surgery or have failed surgical resection 2, 3
- Metastatic/malignant insulinoma with refractory hypoglycemia 4
- Nesidioblastosis (beta-cell hyperplasia) unresponsive to diazoxide 6, 7
- Patients who have failed diazoxide, verapamil, and octreotide 3
Dosing Strategy
Start with subcutaneous pasireotide 0.6 mg twice daily, though some refractory cases may require 0.9 mg twice daily 3, 6. The long-acting release (LAR) formulation at 40-60 mg/month is an alternative for chronic management 6.
Dose Adjustments:
- Reduce to 0.3 mg twice daily in moderate hepatic impairment (Child-Pugh B) 1
- Avoid in severe hepatic impairment (Child-Pugh C) 1
- Titrate by 0.3 mg increments based on response 1
Expected Response and Monitoring
Response typically occurs within days to weeks, with most patients showing improvement by 2 months 2, 3. In the largest systematic review, 41% achieved complete resolution, 23% had partial improvement, and 35% showed no response 2.
Predictors of Poor Response:
- Aggressive/metastatic insulinomas (55% non-response rate vs. 16% in indolent tumors) 2
- Larger tumor size (statistically significant association with failure, P=0.043) 2
Essential Monitoring:
- Frequent glucose checks initially—pasireotide can cause rebound hyperglycemia 1
- Baseline and periodic: ECG, liver function, electrolytes (potassium/magnesium), gallbladder ultrasound 1
- Watch for bradycardia and QT prolongation 1
Critical Pitfalls
The major risk is overcorrection leading to hyperglycemia and diabetes, which occurs in nearly all patients when used for Cushing's disease 1. In hypoglycemia patients, this may be therapeutic, but requires careful titration.
Never use pasireotide as first-line therapy—it was never used initially in any of the reviewed cases 2. Exhaust conventional options first per Endocrine Society guidelines: address underlying causes, trial diazoxide, consider octreotide, optimize nutrition 5.
Pasireotide has 40-times higher affinity for SSTR5 than octreotide, explaining why it works when octreotide fails 3. This higher potency also means greater risk of adverse effects.
Practical Algorithm
Confirm endogenous hyperinsulinism with appropriate testing during hypoglycemia (insulin ≥3 µU/mL, C-peptide ≥0.6 ng/mL, glucose <55 mg/dL) 5
Attempt localization with CT/MRI, endoscopic ultrasound, selective arterial calcium stimulation 5
Trial conventional therapies sequentially: diazoxide → verapamil → octreotide 3
If refractory, consider pasireotide 0.6 mg SC twice daily 3
Monitor intensively for first 2-4 weeks with frequent glucose checks 1
Assess response at 2 months; if inadequate and well-tolerated, increase to 0.9 mg twice daily 1, 2
For aggressive/metastatic disease, anticipate lower response rates and consider combination strategies 2, 4
Special Considerations
In nesidioblastosis, pasireotide LAR has shown sustained efficacy over 2-3 years when diazoxide fails 6, 7. This represents the longest documented successful use for hypoglycemia.
Patients with pre-existing diabetes require careful management—the drug may normalize their glucose initially but could cause hyperglycemia requiring anti-diabetic therapy 6.